Where Will Recursion Pharmaceuticals Be in 3 Years?
Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.
But at the moment, it's burning cash like wild, and there's no sign of when that'll end, as it has nothing in the way of recurring revenue. So let's map out this company's next three years to see if it might be worth buying today, or perhaps in the near future.
Recursion is rare among biotechs because it's developing medicines in-house while banking on big AI collaborations and licensing revenue from its platform to stay afloat in the meantime. By mid-2026, investors will have a much better feel for its chances of commercializing a medicine, not to mention its true attractiveness to potential collaborators, and also the appeal of its data and its platform to would-be licensors. For now, its investing thesis rests on its chances of finding success with at least one of those verticals.
Source Fool.com